Press Releases

June 12, 2019 at 8:00 AM EDT
Altimmune Appoints Will Brown as Chief Financial Officer
GAITHERSBURG, Md. , June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018 .
June 10, 2019 at 8:00 AM EDT
Altimmune Announces Successful Pre-IND Meeting with FDA
Meeting on HepTcell Phase 2 program for treatment of chronic hepatitis B (HBV) GAITHERSBURG, Md. , June 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting
May 8, 2019 at 8:00 AM EDT
Altimmune to Announce First Quarter 2019 Financial Results on May 15
GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,
March 21, 2019 at 4:15 PM EDT
Altimmune to Announce Year End 2018 Financial Results on April 2
GAITHERSBURG, Md. , March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, 2018 before the market open and host a conference call on Tuesday, April 2, 2019
March 19, 2019 at 7:00 AM EDT
Altimmune Announces Positive Results from NasoVAX Extension Study
Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md. , March 19, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company,
March 14, 2019 at 9:00 AM EDT
Altimmune to Participate at 31st Annual ROTH Conference
GAITHERSBURG, Md. , March 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg , Ph.D., President and Chief Executive Officer, and Will Brown , Acting Chief Financial Officer, will provide a corporate overview at
Displaying 1 - 10 of 13

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe